The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
about
Molecular Targeted Intervention for Pancreatic CancerQingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1.Optimum chemotherapy in the management of metastatic pancreatic cancerAntitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
P2860
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The addition of erlotinib to g ...... metastatic pancreatic cancer.
@en
type
label
The addition of erlotinib to g ...... metastatic pancreatic cancer.
@en
prefLabel
The addition of erlotinib to g ...... metastatic pancreatic cancer.
@en
P2093
P2860
P1476
The addition of erlotinib to g ...... metastatic pancreatic cancer.
@en
P2093
Binsah George
David R Fogelman
Gauri Varadhachary
James L Abbruzzese
Michael Overman
Milind Javle
Mohamed A Khalil
Peter Carlson
Robert A Wolff
P2860
P2888
P304
P356
10.1007/S10637-013-9967-2
P577
2013-05-04T00:00:00Z
P6179
1007858470